Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

Apolipoprotein E (apo E)-deficient mice are severely hypercholesterolemic and develop advanced atheromas independent of diet. The C57BL/6 strain differs from most inbred strains by having lower HDL concentrations and a high risk of developing early atherosclerotic lesions when fed an atherogenic diet. The relative HDL deficiency and atherosclerosis susceptibility of the C57BL/6 strain are corrected with the expression of a human apolipoprotein AI (apo AI) transgene in this genetic background. To examine if increases in apo AI and HDL are also effective in minimizing apo E deficiency--induced atherosclerosis, we introduced the human apo AI transgene into the hypercholesterolemic apo E knockout background. Similar elevations of total plasma cholesterol occurred in both the apo E knockout and apo E knockout mice also expressing the human apo AI transgene. The latter animals, however, also showed a two- to threefold increase in HDL and a sixfold decrease in susceptibility to atherosclerosis. This study demonstrates that elevating the concentration of apo AI reduces atherosclerosis in apo E deficient-mice and suggests that elevation of apo AI and HDL may prove to be a useful approach for treating unrelated causes of heightened atherosclerosis susceptibility.

[1]  E. Rubin,et al.  Protein composition determines the anti-atherogenic properties of HDL in transgenic mice , 1993, Nature.

[2]  J. Qiao,et al.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. , 1993, Science.

[3]  E. Rubin,et al.  Atherogenesis Insights from the study of transgenic and gene-targeted mice. , 1993, Trends in cardiovascular medicine.

[4]  K. Marotti,et al.  Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein , 1993, Nature.

[5]  R. Hammer,et al.  Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.

[6]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[7]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[8]  K. Marotti,et al.  The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Rotter,et al.  Reviews, Notes, and Listings: Cardiology: Molecular Genetics of Coronary Artery Disease: Candidate Genes and Processes in Atherosclerosis , 1992, Annals of Internal Medicine.

[11]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[12]  J. Breslow,et al.  Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Krauss,et al.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[15]  B. Paigen,et al.  Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1989, Genetics.

[16]  J. Breslow,et al.  High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. , 1989, The Journal of biological chemistry.

[17]  E. Skamene,et al.  ATH-3, a new gene for atherosclerosis in the mouse. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.

[18]  B. Paigen,et al.  Atherosclerosis in the mouse , 1989 .

[19]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[20]  A. Lusis,et al.  Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Paigen,et al.  Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. , 1987, Atherosclerosis.

[22]  N. Miller.  Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.

[23]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[24]  R. Krauss,et al.  Nondenaturing polyacrylamide gradient gel electrophoresis. , 1986, Methods in enzymology.

[25]  B. Paigen,et al.  Variation in susceptibility to atherosclerosis among inbred strains of mice. , 1985, Atherosclerosis.

[26]  P. Fu,et al.  Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.

[27]  J. Hewitt,et al.  The role of lipids and lipoproteins in atherosclerosis. , 1950, Science.